Résultats de recherche pour “NSE7_SDW-7.2 Exam Cram 🐎 Valid NSE7_SDW-7.2 Test Online 🌂 NSE7_SDW-7.2 Exam Sample 🟧 Search for ➽ NSE7_SDW-7.2 🢪 and obtain a free download on ➤ www.pdfvce.com ⮘ 🙅Latest NSE7_SDW-7.2 Exam Topics”
Detectnet™
Detectnet™
Curium Announces New Indication for Ioflupane I 123 Injection in the U.S.
Curium Announces The Submission Of Its Marketing Authorization Application For [18F]-DCFPyL To The European Medicines Agency
Online Ordering (Dublin, Ireland)
Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.
Nuclear Medicine Outlook: Proven Molybenum-99 Supply Chain Reliability and New Planned Capacity Continue to Benefit Patients
Ioflupane I 123 Injection
NRG and Curium Sign Multi-Year Isotope Production Contract
Curium Prague, Czech Republic
Nuclear medicine education
Welcome customers Thank you for visiting our Nuclear Medicine Education website. Through this website we strive to provide a robust variety of Continuing Education (CE) programs relevant to the Nuclear Medicine Technologist. All courses are structured in a self-paced learning format, conveniently accessible 24 hours a day, 7 days a week, and include course assessments […]
Curium Is the First North American Manufacturer Offering Exclusively 100% LEU Generators
Technescan MAG3™
Kit for the Preparation of Technetium Tc99m Sestamibi Injection
Octreoscan™
Ultra-Technekow™ V4
Curium Acquires Austrian Radiopharmaceuticals Company IASON
Ultra-Technekow™ V4
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
Curium announces publication of [18F]DCFPyL versus [18F]fuoromethylcholine results from European phase III Study (PYTHON trial)
Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol
Octreoscan™
Solar-Recur: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Men with Biochemical Recurrence of Prostate Cancer
Solar-Stage: A Phase 3, Multicenter, Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk, High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection
Curium to Expand Noblesville Facility’s Workforce
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
Kit for the Preparation of Technetium Tc 99m Sestamibi Injection
Pulmotech™ MAA
Curium’s Customers to benefit from Mo-99 Production restart
Ultratag™ RBC
Gallium Citrate Ga 67 Injection
Curium confirms no supply challenges in North America and Europe for its ECLIPSE Phase 3 clinical trial
Ultratag™ RBC
Curium to become major player in the supply on non carrier added Lu-177
Informations et Formations
Xenon Xe 133 Gas
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
Neuraceq
Innovation and growing demand for nuclear medicine drives Curium expansion and 10-year commitment to St. Louis, MO
Curium’s 14 million patients to benefit from regular supply of Mo-99 and TC-99
Curium announces last patient enrolled in their Phase 1/2 SOLAR clinical trial imaging men with histologically-proven metastatic prostate cancer using copper Cu 64 PSMA I&T
RadioMedix and Curium Announce copper Cu 64 dotatate injection Was Granted Priority Review by the U.S. FDA
RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S.
Curium Maryland Heights
RadioMedix et Curium annoncent que le 64Cu-Dotatate a reçu la désignation de Fast Track de la FDA.
Curasight and Curium announce global partnership for uTRACE® in prostate cancer
APhA Annual Meeting & Exposition
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
Accueil
Sodium Iodide I-123 Capsules
RadioMedix and Curium Announce FDA Filing of copper Cu 64 dotatate injection New Drug Application
Pharmacovigilance
Curium et RadioMedix annoncent un accord mondial exclusif pour le développement de 64Cu-Dotatate.
Curium Announces Approval of PulmotechTM MAA (kit for the preparation of technetium Tc 99m albumin aggregated injection) by the U.S. Food and Drug Administration
Xenotron™ I
36th Annual Congress of the European Association of Nuclear Medicine
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
Annoncent un partenariat dans le domaine de l’imagerie thyroïdienne en Allemagne pour permettre la mise en œuvre de solutions d’échographie tomographique en 3D
RadioMedix & Curium Announce CMS Transitional Pass-Through Status for Detectnet™ (copper Cu 64 dotatate injection)
RadioMedix & Curium Announce Permanent HCPCS Code for Detectnet™ (copper Cu 64 dotatate injection)
RadioMedix & Curium Announce Simplified Coding for Detectnet™ (copper Cu 64 dotatate injection)
Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T
ERtracER Solution for Injection
Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T
Curium Confirms No Supply Challenges of 177Lu-PSMA-I&T for ECLIPSE Trial
BNMS – British Nuclear Medicine Society
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
30 Years in NETs
Technescan™ HDP
Contactez-nous
Conditions d’utilisation
Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas
Curium Acquires Finnish Radiopharmaceuticals Company MAP Medical Technologies Oy
Curium Announces Revised Pricing for Technescan MAG3TM (kit for the preparation of technetium Tc 99m mertiatide)
Curium Acquires Zevacor Molecular Strengthening Its PET Portfolio
Curium Announces Drug Master File and Active Substance Master File for Germanium-68 in the U.S. and Europe
PYLCLARI® Luxembourg
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
Curium annonce les premieres doses commerciales en France de PYLCLARI® – un traceur PET innovant 18F-PSMA indique dans le cancer de la prostate
Politique de confidentialité
IBA Molecular et Mallinckrodt Nuclear Medicine LLC s’unissent pour créer une nouvelle société radiopharmaceutique de classe mondiale : Curium
Curium PET France
Curium is attending these global congresses in 2024
Équipe de direction
9ème édition des Journées Francophones de Médecine Nucléaire
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
Congrès national de la Société Française de Radiopharmacie
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]
10èmes édition des Journées Francophones de Médecine Nucléaire
From March 23-25, we will be attending the 9th edition of Journées Francophones de Médecine Nucléaire (JFMN) at the Belfri de Montrouge, in the Paris region, France. Meet Curium team at booth 45B and attend our symposium presentation to gain insights into our multiomic approach to patient care. Symposium Presentation Speakers: PR.PY. SALAÜN, Dépistage de […]